Clinical Trial Shows Improvement In The Prediction Of Death Risk of Lung Cancer

Any diseases can be treated easily if its effect is detected in the early stages. The dreadful diseases lung cancer is taking the life of 1.4 million each year. The effects of the diseases are felt in late stages of the diseases and the person suffering from particular diseases see the death in just 4 to 5 years. The new experimental method that reached out the doctors with the clinical trial helped the doctors with early detection of the diseases. 

The new experimental method in the clinical trial detects the early lung cancer by measuring the activity of fourteen genes within cancerous tissue and assessing a form called non-squamous non-small cell cancer, commonly brought on by tobacco use. The new experimental method has helped many to survive longer life. The new test in the clinical trial would address the inability to detect the diseases in the early stages.

Clinical Trials Begin to Treat Eye Disease With Healthy Steam Cells

Eyes, sensitive part of the body has to be treated with due care. Clinical trials are on rolls to give the most advanced treatment to the eyes through steam cells. The clinical trials use embryonic stem cells to slow or reverse the effects of macular degeneration and dystrophy. The patients suffering from these particular disorders related to eye will have the steam cells injected into their eyes giving their acceptance for the observation in the clinical trials. The expectation from the clinical trial is to slow, halt or even reverses the effects of the dystrophy by injecting healthy retinal cells into the eye.

Dystrophy is the main reason for blindness in the young people. The trail phase of the steam cell therapy goes with the normal clinical trial process and adheres on knowing the safety of the stem cell therapy in the early phases. The success of the clinical expects the new RPE (retinal pigment epithelial cells) injected into the will grow gradually and restore the damaged retina to healthy state.

Clinical Trials for Medical Devices

The far believed misconception is clinical trials are conducted only to test the safety and efficiency of the unknown drugs. The fact states that clinical trials run to test the efficiency of the medical devices too. The importance of medical devices has risen up with the growing technology in the medical sciences. The new medical devices that are used to provide advance treatment to the patients have to surrender for the clinical trial testing in order to ensure the safety of the patient that is getting treated. 

Clinical testing for these medical devices is shifting to the developed countries like China and India to cut down the clinical trial cost. One more reason for the clinical trial push to these developing countries is regulation for conducting clinical trial in these developing countries is almost nonexistent. 

Due to the difference in the regulatory protocols, bringing the medical devices into the market of the other countries proved to be difficult. All the patients over the globe were not in accesses to the new medical devices. To bring down the complexity in clinical trial of the medical device, countries like Japan, Europe and US have agreed on a standard that, at minimum, met the regulatory requirements that already exist in their respective countries.

Improvements In The Clinical Trials Can Be Achieved

Drug development in medical field is a lengthy process. A failed project always is a costly mistake. Though the process of the clinical trial comes at the end of the drug life cycle of the drug development, it plays a crucial role in the success of the drug in the medical world. Clinical trials are the ones that decide the efficiency and safety of the drug before it enters into the market. To reduce the failure rate in the drug development process, there is need to bring many changes to improve the clinical trial.

The improved strategies applied in the clinical trial should aim at cutting down the length of time. The drug development process with the help of the clinical trials should identify advanced medicine options to the patients in the clinical trials. Recent history of the clinical trials showed grater failure rate in when processed in the rigid mode. The new theory says there should be a chance to make the necessary changes in the clinical trial at the intermediate level. Adaptive clinical trials would be an effective measure to bring the necessary improvements in the clinical trial.

Black Mark Warnings Of FDA On Medicines To Denote Heavy Risks

The drugs from the clinical trial enter the market only after receiving the approval from FDA. Few medicines that come out of the clinical trial put risks on the customers if taken in the heavy dosages. Intake of such medicine may cure few health disorders, but heavy intake of the same drug puts you to possible risks. To caution the end user against such risk, FDA has stamps a black mark on the medicines rather than banding it. Tough the caution given by FDA on the medicine curbed the usage of the medicine. The action taken by the Food Drug Approval agency is not enough to reduce the possible risks of the medicine in the market. 

Public takes the drug approved by FDA with greater assurance. More innovative steps are required from FDA to caution the public against the risk of heavy intake of the drugs that have stamped the black mark.

Clinical Trial Recruitment Of The Patient Needs Much More Than The Social Media

Social media has been the buzz around the world to exchange the conversation, the fever of social media has spread to clinical trial as well. I agree that social media like Face book and twitter stand as important source in increasing the awareness about ongoing clinical trials and encourage their participation in the clinical trial. Social media establishes an unbiased platform between the investigator and participants of the clinical trial but, it does not clear the complexity involved in understanding the complexity of the clinical trial.

The effectiveness of the clinical trial conversation can be established only when the online communication is established as the part of wider communication like radio, print, search engine marketing, study specific websites, etc. The conversation can engage potential subjects only when the sponsor site provides powerful and quality information. 

Use of the medical jargon should be avoided to the maximum, the complexity of the clinical trial should be explained, give the human face to the study.